Rapa Therapeutics LLC Report issue

For profit Phase 1 Phase 2
Founded: Rockville MD United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04176380
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rapa Therapeutics LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Motor Neuron Disease (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5